<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Localized lichen myxedematosus
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Localized lichen myxedematosus
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Localized lichen myxedematosus
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Franco Rongioletti, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jeffrey Callen, MD, FACP, FAAD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Abena O Ofori, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 02, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H494307203">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lichen myxedematosus (LM; also called papular mucinosis) is a chronic idiopathic cutaneous mucinosis characterized by lichenoid papules, nodules, and/or plaques; mucin deposition and a variable degree of fibrosis in the dermis; and an absence of associated thyroid disease [
         <a href="#rid1">
          1
         </a>
         ]. LM includes three clinicopathologic subsets (
         <a class="graphic graphic_table graphicRef111847" href="/z/d/graphic/111847.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Localized LM
         </strong>
         – A localized papular form of LM with a benign course and lack of systemic involvement.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scleromyxedema
         </strong>
         – A diffuse/generalized papular and sclerodermoid form of LM associated with monoclonal gammopathy and systemic, potentially fatal, manifestations. (See
         <a class="medical medical_review" href="/z/d/html/89048.html" rel="external">
          "Scleromyxedema"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Atypical or intermediate forms of LM
         </strong>
         – LM with atypical features or overlapping features of localized LM and scleromyxedema.
        </p>
        <p>
        </p>
        <p>
         Localized LM is divided into four subtypes that are differentiated based upon clinical and histopathologic features (
         <a class="graphic graphic_table graphicRef111850" href="/z/d/graphic/111850.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef111839 graphicRef111840 graphicRef111841 graphicRef111842 graphicRef111843" href="/z/d/graphic/111839.html" rel="external">
          picture 1A-E
         </a>
         ). The four subtypes are:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acral persistent papular mucinosis (APPM)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discrete papular lichen myxedematosus (DPLM)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cutaneous mucinosis of infancy (CMI)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nodular lichen myxedematosus (nodular LM)
        </p>
        <p>
        </p>
        <p>
         The clinical features, diagnosis, and management of localized LM will be reviewed here. Scleromyxedema and myxedema associated with thyroid disease are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/89048.html" rel="external">
          "Scleromyxedema"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7826.html" rel="external">
          "Pretibial myxedema (thyroid dermopathy) in autoimmune thyroid disease"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3600118832">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Epidemiologic data on localized LM are limited. Localized LM appears to be rare and less prevalent than scleromyxedema, though the frequency of this disorder is probably underestimated. Acral persistent papular mucinosis (APPM) is the most frequently reported variant of localized LM, with fewer than 50 reports of patients with APPM in the literature.
        </p>
        <p>
         The primary populations affected by the various subtypes of localized LM differ. APPM usually develops in adults and is more frequent in women than men. In a literature review that evaluated reports of 32 patients with APPM, the mean patient age was 50 years (range 14 to 77 years) and 25 of the 32 patients (78 percent) were female. Discrete papular lichen myxedematosus (DPLM) affects adults of both sexes [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Nodular lichen myxedematosus (nodular LM) has primarily been reported in young adults [
         <a href="#rid4">
          4
         </a>
         ] but has also occurred in a child [
         <a href="#rid5">
          5
         </a>
         ]. Cutaneous mucinosis of infancy (CMI) is present at birth or appears in early infancy [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H270825587">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathogenesis of LM is unknown. The main hypothesis is that circulating cytokines known to stimulate glycosaminoglycan synthesis and fibroblast proliferation in the skin, such as interleukin (IL) 1, tumor necrosis factor (TNF)-alpha, and transforming growth factor (TGF)-beta, play a role [
         <a href="#rid6">
          6
         </a>
         ]. In addition, it has been suggested that an intrinsic abnormality of fibroblasts in patients with LM may result in increased glycosaminoglycan synthesis [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Clinical observations suggest that other factors, such as viral infections (eg, HIV infection), surgery (eg, joint replacement) or other physical trauma, radiation therapy, and drugs, may stimulate mucin and collagen production, contributing to the development of localized LM [
         <a href="#rid8">
          8,9
         </a>
         ]. In addition, discrete papular lichen myxedematosus (DPLM) has been described in the setting of toxic oil syndrome caused by contaminated rapeseed oil and L-tryptophan-associated eosinophilia-myalgia syndrome [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7557.html" rel="external">
          "Risk factors for and possible causes of systemic sclerosis (scleroderma)", section on 'Contaminated rapeseed oil'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7557.html" rel="external">
          "Risk factors for and possible causes of systemic sclerosis (scleroderma)", section on 'L-tryptophan'
         </a>
         .)
        </p>
        <p>
         A pathogenic mechanism that involves paraproteins acting as autoantibodies that stimulate fibroblasts to proliferate and overproduce mucin has been proposed for the scleromyxedema subtype of LM. However, localized LM is unlikely to share this mechanism, given the typical absence of associated paraproteinemia. A promoting role of TGF-beta and abnormally high secretion of IL-4, a profibrotic cytokine, has been associated with scleromyxedema, but a similar role for these cytokines in localized LM needs confirmation [
         <a href="#rid11">
          11,12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/89048.html" rel="external">
          "Scleromyxedema", section on 'Pathogenesis'
         </a>
         .)
        </p>
        <p>
         A genetic predisposition to localized LM has been proposed based upon a report of a child with cutaneous mucinosis of infancy (CMI) whose father had similar cutaneous lesions during his childhood and a report of acral persistent papular mucinosis (APPM) in two sisters [
         <a href="#rid13">
          13,14
         </a>
         ]. Such occurrences are rare; in general, a family history of localized LM is absent.
        </p>
        <p class="headingAnchor" id="H83271999">
         <span class="h1">
          ASSOCIATED CONDITIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of conditions have been linked to localized LM in case reports:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection
         </strong>
         – There are multiple reports of discrete papular lichen myxedematosus (DPLM) occurring in association with HIV infection; HIV infection usually antedates the development of the skin lesions [
         <a href="#rid15">
          15,16
         </a>
         ]. In addition, an association of DPLM with chronic hepatitis due to hepatitis C virus infection has been reported, most often in Japan [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monoclonal gammopathy and hypergammaglobulinemia
         </strong>
         – An absence of associated monoclonal gammopathy is a diagnostic criterion for localized LM, and the presence of monoclonal gammopathy in a patient with clinical and histologic findings consistent with localized LM is considered an atypical presentation (
         <a class="graphic graphic_table graphicRef111850" href="/z/d/graphic/111850.html" rel="external">
          table 2
         </a>
         ). DPLM associated with monoclonal gammopathy has been reported [
         <a href="#rid17">
          17
         </a>
         ]. In a case series of four patients with non-HIV-associated DPLM and monoclonal gammopathy, progression to scleromyxedema, multiple myeloma, or systemic involvement did not occur during a mean follow-up period of 34 months (range 6 to 72 months) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Of note, most of the reported patients with HIV-associated DPLM have had associated polyclonal hypergammaglobulinemia [
         <a href="#rid16">
          16
         </a>
         ]. Paraproteinemia has also been reported in a minority of patients with HIV-associated DPLM and may occur in relation to underlying HIV infection [
         <a href="#rid16">
          16,18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8036.html" rel="external">
          "HIV infection and malignancy: Management considerations", section on 'Plasma cell disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other
         </strong>
         – Localized LM occurring in association with immunoglobulin A (IgA) nephropathy, joint replacement, or drug exposure, including biologic therapy (anti-tumor necrosis factor [TNF]-alpha and anti-interleukin [IL] 12/23), has been described in anecdotal case reports [
         <a href="#rid9">
          9,19-21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1743988708">
         <span class="h1">
          CLINICAL FINDINGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The four subtypes of localized LM exhibit distinct clinical findings. Atypical LM can exhibit overlapping features of the subtypes (
         <a class="graphic graphic_table graphicRef111850" href="/z/d/graphic/111850.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid22">
          22-24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4246964517">
         <span class="h2">
          Acral persistent papular mucinosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Acral persistent papular mucinosis (APPM) presents as multiple white to skin-colored, 2 to 5 mm, firm, waxy papules limited to the extensor surfaces of the hands, wrists, and sometimes forearms (
         <a class="graphic graphic_picture graphicRef111839" href="/z/d/graphic/111839.html" rel="external">
          picture 1A
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3168275592">
         <span class="h2">
          Discrete papular lichen myxedematosus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Discrete papular lichen myxedematosus (DPLM) usually manifests as waxy, skin-colored or reddish, 2 to 5 mm papules. The papules develop on the trunk and limbs in a symmetrical or asymmetrical pattern (
         <a class="graphic graphic_picture graphicRef111840 graphicRef111841" href="/z/d/graphic/111840.html" rel="external">
          picture 1B-C
         </a>
         ). The number of papules can vary from few to hundreds [
         <a href="#rid1">
          1,3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2346203216">
         <span class="h2">
          Cutaneous mucinosis of infancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous mucinosis of infancy (CMI) presents as firm, opalescent to skin-colored papules of less than 1 cm in diameter. The papules can be symmetrically distributed and densely grouped, linear and localized, or more generalized and arranged in rows or coalescing into plaques. The eruption is distributed over the trunk, neck, and extremities (
         <a class="graphic graphic_picture graphicRef111842" href="/z/d/graphic/111842.html" rel="external">
          picture 1D
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2949338638">
         <span class="h2">
          Nodular lichen myxedematosus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nodular lichen myxedematosus (nodular LM) presents with multiple firm, slightly elevated nodules (at least 1 cm in diameter) on the limbs and trunk (
         <a class="graphic graphic_picture graphicRef111843" href="/z/d/graphic/111843.html" rel="external">
          picture 1E
         </a>
         ). The nodules appear shiny and yellowish to skin-colored [
         <a href="#rid2">
          2,5
         </a>
         ]. A mild papular eruption may also be present.
        </p>
        <p class="headingAnchor" id="H770060089">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         A diagnosis of localized LM is made based upon the detection of consistent clinical and histologic findings and the absence of findings suggestive of scleromyxedema or other diseases. The diagnostic criteria include [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Papular or nodular eruption consistent with one of the subtypes of localized LM
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Histologic findings of mucin deposition and variable degree of fibroblast proliferation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Absence of gammopathy, thyroid disease, and systemic involvement
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4101898957">
         <span class="h2">
          Skin biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although a diagnosis of localized LM may be suspected based upon the physical findings, a skin biopsy is required for diagnosis. A 4 to 5 mm punch biopsy provides a sufficient specimen from patients with papules or plaques. An incisional or excisional biopsy can be performed for nodular lesions. (See
         <a class="medical medical_review" href="/z/d/html/5577.html" rel="external">
          "Skin biopsy techniques"
         </a>
         .)
        </p>
        <p>
         The expected histologic findings differ among the clinical subtypes of localized LM:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Discrete papular lichen myxedematosus (DPLM)
         </strong>
         (
         <a class="graphic graphic_picture graphicRef111845" href="/z/d/graphic/111845.html" rel="external">
          picture 2
         </a>
         )
         <strong>
         </strong>
         [
         <a href="#rid25">
          25
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Diffuse deposition of mucin interspersed with large collagen bundles in the reticular dermis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Variable degree of fibroblast proliferation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perivascular lymphocytic infiltrate (variably present)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Acral persistent papular mucinosis (APPM)
         </strong>
         (
         <a class="graphic graphic_picture graphicRef111844" href="/z/d/graphic/111844.html" rel="external">
          picture 3
         </a>
         )
         <strong>
         </strong>
         [
         <a href="#rid25">
          25,26
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Focal dermal mucin deposition in the upper dermis with sparing of the subepidermal zone (Grenz zone)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Lack of increase in dermal fibroblasts
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Cutaneous mucinosis of infancy (CMI)
         </strong>
         [
         <a href="#rid5">
          5,25
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Focal, well-circumscribed deposit of mucin in the papillary dermis (mucin deposition may occur in the reticular dermis)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of fibroblast proliferation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perivascular mononuclear cell infiltrate in the superficial dermis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Immunohistochemistry for CD1a, CD117, and CD68 is negative or noncontributory
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nodular lichen myxedematosus (nodular LM)
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Collagen fibers separated by mucin deposition in the reticular dermis
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Variable degree of fibroblast proliferation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Perivascular infiltrate of lymphocytes and plasma cells (variably present)
        </p>
        <p>
        </p>
        <p>
         Deposition of mucin can be confirmed with an Alcian blue stain (pH 2.5) or colloidal iron stain.
        </p>
        <p class="headingAnchor" id="H2069845863">
         <span class="h2">
          Laboratory tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the overlap in the clinical and histologic findings of localized LM and scleromyxedema, patients should be evaluated for monoclonal gammopathy, a characteristic associated finding in scleromyxedema. Laboratory testing should also be performed to distinguish LM from myxedema associated with thyroid disease.
        </p>
        <p>
         Our initial laboratory work-up consists of the following tests:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum protein electrophoresis and immunofixation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid-stimulating hormone level
        </p>
        <p>
        </p>
        <p>
         The results of these tests should be normal in patients with localized LM.
        </p>
        <p>
         In addition, testing for HIV infection is often performed for patients with clinical and histologic findings consistent with DPLM given the association of DPLM with HIV infection. Testing for hepatitis B and C virus infection is also reasonable for patients with DPLM and risk factors or signs or symptoms of this disease. No other laboratory abnormalities are expected in patients with localized LM. (See
         <a class="local">
          'Associated conditions'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/3672.html" rel="external">
          "Clinical manifestations and natural history of chronic hepatitis C virus infection", section on 'Clinical features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1056056986">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of localized LM includes scleromyxedema and a variety of other cutaneous disorders:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Scleromyxedema
         </strong>
         – Localized LM and scleromyxedema are considered to be on the same disease spectrum. Clinical, histologic, and laboratory findings aid in distinguishing these disorders. Clinically, the eruption of scleromyxedema is more diffuse and sclerodermoid (
         <a class="graphic graphic_picture graphicRef91118 graphicRef91120" href="/z/d/graphic/91118.html" rel="external">
          picture 4A-B
         </a>
         ). The classic histopathologic findings of scleromyxedema are a microscopic triad of mucin deposition, fibroblast proliferation, and fibrosis; rarely, an interstitial granuloma annulare-like pattern is detected. Unlike localized LM, scleromyxedema occurs in association with monoclonal gammopathy and can have a variety of extracutaneous manifestations. (See
         <a class="medical medical_review" href="/z/d/html/89048.html" rel="external">
          "Scleromyxedema"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other disorders
         </strong>
         – The differential diagnosis of localized LM also includes cutaneous papular eruptions, particularly those that may present with white, skin-colored, or erythematous, smooth papules, plaques, or nodules, such as granuloma annulare, molluscum contagiosum, acrokeratoelastoidosis, lichen amyloidosis, lichen planus, and eruptive collagenoma as well as other forms of cutaneous mucinosis (eg, pretibial myxedema, reticulated erythematous mucinosis, follicular mucinosis). Review of the clinical findings and a skin biopsy distinguishes localized LM from these disorders.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Additional disorders in the differential diagnosis of cutaneous mucinosis of infancy (CMI) are self-healing juvenile cutaneous mucinosis (SHJCM) and mucinous nevus. SHJCM is characterized by an acute eruption of papules that may coalesce to form linear infiltrated plaques on the face, neck, scalp, abdomen, and/or thighs of children. Mucinous subcutaneous nodules on the face associated with periorbital swelling and on periarticular areas are sometimes predominant features. Patients can have systemic symptoms such as fever, arthralgias, weakness, and muscle tenderness. A skin biopsy will show a fibroblastic reactive proliferation involving the subcutaneous fat similar to nodular or proliferative fasciitis, with mucin deposited throughout the dermis and subcutis [
         <a href="#rid27">
          27
         </a>
         ]. Spontaneous resolution typically occurs within a few weeks to several months.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Mucinous nevus is a congenital or acquired hamartomatous connective tissue nevus that manifests as a unilateral eruption of multiple brown to skin-colored papules or plaques in a linear or zosteriform arrangement [
         <a href="#rid28">
          28
         </a>
         ]. The classic histopathologic findings are a band-like deposition of mucin that fills the upper dermis and loss of elastic fibers.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3850956185">
         <span class="h1">
          PROGNOSIS AND FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         The cutaneous findings of localized LM may progress over time and generally persist. Spontaneous regression of discrete papular lichen myxedematosus (DPLM) has been reported in some patients with DPLM-associated HIV infection [
         <a href="#rid29">
          29
         </a>
         ]. Although localized LM and scleromyxedema belong to a spectrum of disease, progression of localized LM to scleromyxedema has not been proven.
        </p>
        <p>
         Given the benign and skin-limited nature of localized LM, clinical and laboratory follow-up is not needed for patients with typical disease presentations.
        </p>
        <p class="headingAnchor" id="H1639919262">
         <span class="h1">
          MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Localized LM is a benign condition for which treatment is not required. We typically reassure patients regarding the benign nature of localized LM and do not initiate treatment.
        </p>
        <p>
         However, the appearance of localized LM is bothersome for some patients and has led to attempts at treatment. There is no uniformly effective therapy. Treatments that have seemed beneficial for individual patients with discrete papular lichen myxedematosus (DPLM) or acral persistent papular mucinosis (APPM) include medical therapies (topical or intralesional corticosteroids and topical calcineurin inhibitors [
         <a href="#rid30">
          30
         </a>
         ]) and destructive surgical therapies (dermabrasion, electrosurgery [
         <a href="#rid31">
          31
         </a>
         ], carbon dioxide laser, erbium:yttrium aluminum garnet laser [
         <a href="#rid32">
          32
         </a>
         ]). However, responses to these interventions vary, and surgical therapies are associated with risk for scarring. Partial or complete resolution of HIV-associated DPLM within several months after the initiation or a change in antiretroviral therapy has been documented in case reports [
         <a href="#rid16">
          16
         </a>
         ]. In addition, a patient with DPLM had resolution of skin disease following combination antiviral therapy for chronic hepatitis C virus infection [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Improvement of nodular lichen myxedematosus (nodular LM) with intralesional corticosteroid injections or oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         has been described in case reports [
         <a href="#rid4">
          4
         </a>
         ]. Given the benign course and the occurrence of cutaneous mucinosis of infancy (CMI) in young children, CMI generally is not treated.
        </p>
        <p class="headingAnchor" id="H1139306254">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Localized lichen myxedematosus (LM) is a skin-limited form of LM characterized by lichenoid papules, nodules, and/or plaques; mucin deposition and a variable degree of fibrosis in the dermis; and an absence of associated monoclonal gammopathy, thyroid disease, or systemic involvement. Localized LM should be distinguished from scleromyxedema, a form of LM that presents with a diffuse/generalized papular and sclerodermoid eruption, monoclonal gammopathy, and the potential for systemic involvement (
         <a class="graphic graphic_picture graphicRef91118 graphicRef91120" href="/z/d/graphic/91118.html" rel="external">
          picture 4A-B
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/89048.html" rel="external">
          "Scleromyxedema"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         There are four subtypes of localized LM: acral persistent papular mucinosis (APPM), discrete papular lichen myxedematosus (DPLM), cutaneous mucinosis of infancy (CMI), and nodular lichen myxedematosus (nodular LM). APPM, DPLM, and nodular LM typically occur in adults. CMI is present at birth or develops in early infancy. DPLM can occur in association with HIV infection. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Associated conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Atypical presentations of localized LM with monoclonal gammopathy or overlapping features of the different subtypes have been reported. (See
         <a class="local">
          'Associated conditions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The classic clinical manifestations of the subtypes of localized LM are (see
         <a class="local">
          'Clinical findings'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          APPM
         </strong>
         – Multiple white to skin-colored, firm, waxy papules limited to the extensor surfaces of the hands, wrists, and/or forearms (
         <a class="graphic graphic_picture graphicRef111839" href="/z/d/graphic/111839.html" rel="external">
          picture 1A
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DPLM
         </strong>
         – Multiple waxy, skin-colored or reddish papules on the trunk and/or limbs in a symmetrical or asymmetrical pattern (
         <a class="graphic graphic_picture graphicRef111840 graphicRef111841" href="/z/d/graphic/111840.html" rel="external">
          picture 1B-C
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          CMI
         </strong>
         – Firm, opalescent to skin-colored papules in a grouped, linear, or generalized distribution (
         <a class="graphic graphic_picture graphicRef111842" href="/z/d/graphic/111842.html" rel="external">
          picture 1D
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Nodular LM
         </strong>
         – Multiple firm, shiny, yellowish to skin-colored nodules on the limbs and trunk (see
         <a class="local">
          'Nodular lichen myxedematosus'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A diagnosis of localized LM is made based upon review of the clinical, histologic, and laboratory findings. The diagnostic criteria include (see
         <a class="local">
          'Diagnosis'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Papular or nodular eruption consistent with one of the subtypes of localized LM
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Histologic findings of mucin deposition and variable degree of fibroblast proliferation
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Absence of gammopathy, thyroid disease, and systemic involvement
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In most patients, localized LM persists. Spontaneous resolution of HIV-associated DPLM has been reported. Progression to scleromyxedema does not appear to occur. (See
         <a class="local">
          'Prognosis and follow-up'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Localized LM is a benign condition. Treatment is not necessary. A variety of medical and surgical treatments have been tried with variable results. (See
         <a class="local">
          'Management'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Rebora A. Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema. J Am Acad Dermatol 2001; 44:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F. Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease. Semin Cutan Med Surg 2006; 25:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Concheiro J, Pérez-Pérez L, Peteiro C, et al. Discrete papular lichen myxoedematosus: a rare subtype of cutaneous mucinosis. Clin Exp Dermatol 2009; 34:e608.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogita A, Higashi N, Hosone M, Kawana S. Nodular-type lichen myxedematosus: a case report. Case Rep Dermatol 2010; 2:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F. Primary paediatric cutaneous mucinoses. Br J Dermatol 2020; 182:29.
          </a>
         </li>
         <li class="breakAll">
          Rongioletti F, Rebora A. Mucinoses. In: Dermatology, 3rd ed, Bolognia J, Jorizzo JL, Schaffer JV, et al. (Eds), Elsevier, Philadelphia 2012. Vol 1, p.687.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferrarini M, Helfrich DJ, Walker ER, et al. Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts. J Rheumatol 1989; 16:837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernandez-Flores A, Barja-Lopez JM, Saeb-Lima M. Papular mucinosis of the breast after radiation therapy. J Cutan Pathol 2014; 41:969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haught JM, Serrao R, English JC 3rd. Localized cutaneous mucinosis after joint replacement. Arch Dermatol 2008; 144:1399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Rebora A. Cutaneous toxic mucinoses. J Am Acad Dermatol 1992; 26:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mahévas T, Arnulf B, Bouaziz JD, et al. Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood 2020; 135:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalli F, Cioni M, Parodi A, et al. Increased frequency of interleukin-4 and reduced frequency of interferon-γ and IL-17-producing CD4+ and CD8+ cells in scleromyxedema. J Eur Acad Dermatol Venereol 2020; 34:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Podda M, Rongioletti F, Greiner D, et al. Cutaneous mucinosis of infancy: is it a real entity or the paediatric form of lichen myxoedematosus (papular mucinosis)? Br J Dermatol 2001; 144:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menni S, Cavicchini S, Brezzi A, et al. Acral persistent papular mucinosis in two sisters. Clin Exp Dermatol 1995; 20:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Ghigliotti G, De Marchi R, Rebora A. Cutaneous mucinoses and HIV infection. Br J Dermatol 1998; 139:1077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbott RA, Calonje E, Almaani N, et al. Widespread papules in a patient with human immunodeficiency virus. Papular mucinosis (PM) in association with HIV infection. Clin Exp Dermatol 2010; 35:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hermans C, Goldscheider I, Ruzicka T, Rongioletti F. Atypical discrete papular lichen myxedematosus associated with monoclonal gammopathy: report of four cases and review of the literature. J Eur Acad Dermatol Venereol 2016; 30:2048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarantini G, Zerboni R, Muratori S, et al. Lichen myxoedematosus in a patient with AIDS. Br J Dermatol 1996; 134:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang P, Yang H, Ran Y. Localized papular mucinosis with IgA nephropathy: a case report. Arch Dermatol 2011; 147:599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesiak A, Włodarczyk M, Sobolewska A, et al. Can biologic treatment induce cutaneous focal mucinosis? Postepy Dermatol Alergol 2014; 31:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montero-Vilchez T, Martinez-Lopez A, Cuenca-Barrales C, et al. Nodular lichen myxoedematous: a new adverse event associated with ustekinumab. Australas J Dermatol 2020; 61:e344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zeng YP, Ma DL. Atypical case of discrete papular mucinosis involving acral and nuchal regions in an adult. J Dtsch Dermatol Ges 2012; 10:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reserva J, Marchalik R, Braniecki M. Discrete ('acral nonpapular') localised lichen myxedematosus. BMJ Case Rep 2015; 2015.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen CW, Tsai TF, Chang SP, et al. Congenital cutaneous mucinosis with spontaneous regression: an atypical cutaneous mucinosis of infancy? Clin Exp Dermatol 2009; 34:804.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Rebora A. Cutaneous mucinoses: microscopic criteria for diagnosis. Am J Dermatopathol 2001; 23:257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Rebora A, Crovato F. Acral persistent papular mucinosis: a new entity. Arch Dermatol 1986; 122:1237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luchsinger I, Coulombe J, Rongioletti F, et al. Self-healing juvenile cutaneous mucinosis: Clinical and histopathologic findings of 9 patients: The relevance of long-term follow-up. J Am Acad Dermatol 2018; 78:1164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Rebora A. Mucinous nevus. Arch Dermatol 1996; 132:1522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Depaire-Duclos F, Renuy F, Dandurand M, Guillot B. Papular mucinosis with rapid spontaneous regression in an HIV-infected patient. Eur J Dermatol 1998; 8:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rongioletti F, Zaccaria E, Cozzani E, Parodi A. Treatment of localized lichen myxedematosus of discrete type with tacrolimus ointment. J Am Acad Dermatol 2008; 58:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           André Jorge F, Mimura Cortez T, Guadalini Mendes F, et al. Treatment of acral persistent papular mucinosis with electrocoagulation. J Cutan Med Surg 2011; 15:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Graves MS, Lloyd AA, Ross EV. Treatment of acral persistent papular mucinosis using an Erbium-YAG laser. Lasers Surg Med 2015; 47:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones KM, Shelton ME, Soldano AC, Campbell J. Resolution of Atypical Lichen Myxedematosus Following Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir-Velpatasvir Combination Therapy. JAMA Dermatol 2018; 154:1094.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 110154 Version 6.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11174386" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Updated classification of papular mucinosis, lichen myxedematosus, and scleromyxedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16908401" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lichen myxedematosus (papular mucinosis): new concepts and perspectives for an old disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19486062" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Discrete papular lichen myxoedematosus: a rare subtype of cutaneous mucinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21509202" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Nodular-type lichen myxedematosus: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30977896" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Primary paediatric cutaneous mucinoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30977896" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Primary paediatric cutaneous mucinoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2778769" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Scleromyxedema serum increases proliferation but not the glycosaminoglycan synthesis of dermal fibroblasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25370988" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Papular mucinosis of the breast after radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18936415" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Localized cutaneous mucinosis after joint replacement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1583189" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Cutaneous toxic mucinoses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32027747" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31912592" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Increased frequency of interleukin-4 and reduced frequency of interferon-γand IL-17-producing CD4+ and CD8+ cells in scleromyxedema.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11260021" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Cutaneous mucinosis of infancy: is it a real entity or the paediatric form of lichen myxoedematosus (papular mucinosis)?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8593726" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Acral persistent papular mucinosis in two sisters.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9990377" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Cutaneous mucinoses and HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20831608" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Widespread papules in a patient with human immunodeficiency virus. Papular mucinosis (PM) in association with HIV infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27422288" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Atypical discrete papular lichen myxedematosus associated with monoclonal gammopathy: report of four cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8763438" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lichen myxoedematosus in a patient with AIDS.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21576580" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Localized papular mucinosis with IgA nephropathy: a case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25610359" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Can biologic treatment induce cutaneous focal mucinosis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32285931" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Nodular lichen myxoedematous: a new adverse event associated with ustekinumab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22313743" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Atypical case of discrete papular mucinosis involving acral and nuchal regions in an adult.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25721845" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Discrete ('acral nonpapular') localised lichen myxedematosus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19077089" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Congenital cutaneous mucinosis with spontaneous regression: an atypical cutaneous mucinosis of infancy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11391115" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cutaneous mucinoses: microscopic criteria for diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3777968" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Acral persistent papular mucinosis: a new entity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29066274" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Self-healing juvenile cutaneous mucinosis: Clinical and histopathologic findings of 9 patients: The relevance of long-term follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8961894" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Mucinous nevus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9683868" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Papular mucinosis with rapid spontaneous regression in an HIV-infected patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18280368" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Treatment of localized lichen myxedematosus of discrete type with tacrolimus ointment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21781629" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Treatment of acral persistent papular mucinosis with electrocoagulation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25952726" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Treatment of acral persistent papular mucinosis using an Erbium-YAG laser.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30140911" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Resolution of Atypical Lichen Myxedematosus Following Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir-Velpatasvir Combination Therapy.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
